The global peptide active pharmaceutical ingredient (API) market is experiencing transformational growth, driven primarily by explosive demand for GLP-1 receptor agonists used in diabetes and obesity treatments. The market was worth USD 5.15 billion in 2025 and is expected to grow at a CAGR of 15.24% between 2026 and 2031, reaching USD 12.1 billion by 2031. By 2031, nearly half of all global peptide API market revenue will derive from GLP-1 products alone.
This explosive growth, particularly between 2022-2024 (27.3% YoY growth), has catalyzed unprecedented capacity expansion and investment across the entire supply chain. Beyond 2025, growth stabilizes to 15.2% annually, reflecting maturation in manufacturing rather than a slowdown in underlying drug demand.
Oncology peptides represent the second-largest segment at 15.9% market share, growing at 12.76% CAGR by value, driven by LHRH analogs for prostate/breast cancer applications. Hormonal peptides is the third largest segment, growing at 9.28% CAGR by value.
This explosive growth, particularly between 2022-2024 (27.3% YoY growth), has catalyzed unprecedented capacity expansion and investment across the entire supply chain. Beyond 2025, growth stabilizes to 15.2% annually, reflecting maturation in manufacturing rather than a slowdown in underlying drug demand.
Oncology peptides represent the second-largest segment at 15.9% market share, growing at 12.76% CAGR by value, driven by LHRH analogs for prostate/breast cancer applications. Hormonal peptides is the third largest segment, growing at 9.28% CAGR by value.
Scope of Global Peptide API Market Strategic Research Report 2026-2031
- This report provides forecast data by value and volume for the global peptide API market, with 2025 as the base year and forecasting to 2031.
- This report provides segment by type (GLP-1 Receptor Agonist API, Hormonal Peptide API, Oncology Peptide API, Antimicrobial Peptide API, CNS/Neuropeptide API, Cardiovascular Peptide API, Immunology/Rare Disease API, Research/Cosmetics & Other) forecast data by value and volume. This report provides application segments (Diabetes & Obesity/GLP-1-GIP, Oncology, Rare Diseases/Orphan Drugs, Cardiovascular, Infectious Diseases/Antimicrobial, CNS/Neurology, Reproductive Health/Hormonal, Research/Diagnostics & Other) forecast data by value and volume.
- This report provides region-wise and country-level forecast data.
- This report identifies key growth drivers and inhibitors affecting the global peptide API market.
- This report provides company profiles for key manufacturers.
- This report provides Porter's Five Forces, PESTLE, and SWOT analysis.
- This report identifies key future trends through 2031.
Who can use the Global Peptide API Market Research Report?
This research report is ideal for people who wish to understand the peptide API market. Some of the intended users are:- C-level executives and Company Directors in pharmaceutical manufacturing and CDMO companies
- Investment managers and Financial professionals
- Anyone operating in the peptide API value chain.
Table of Contents
1. Executive Summary2. Industry Overview & Forecast
3. Market Segmentation by Type
4. Market Segmentation by Application
5. Regional Market Forecast
6. Country-Level Market Forecast
7. Growth Drivers & Inhibitors
8. Key Company Profiles
9. Competitive Landscape
10. Porter's Five Forces Analysis
11. PESTLE Analysis
12. SWOT Analysis
13. Future Trends & Outlook
Companies Mentioned
- Bachem (Julius Bachem AG)
- PolyPeptide Group
- CordenPharma International
- WuXi STA (WuXi AppTec Peptide)
- Hybio Pharmaceutical
- AmbioPharm Inc.
- ScinoPharm Taiwan
- Almac Group (Almac Sciences)
- Piramal Pharma Solutions
- CPC Scientific Inc.
- GL Biochem (Shanghai) Ltd.
